Safety, efficacy, and onset of a novel botulinum toxin type A (Nabota) for the treatment of glabellar frown lines: a single-arm, prospective, phase 4 clinical study.
- Author:
Sinyoung SONG
1
;
Yeon Hoon LEE
;
Joon Pio HONG
;
Tae Suk OH
Author Information
- Publication Type:Original Article
- Keywords: Botulinum toxins, type A; Glabellar frown line; Safety; Efficacy; Onset
- MeSH: Botulinum Toxins*; Botulinum Toxins, Type A*; Clinical Study*; Humans; Injections, Intramuscular; Prospective Studies*; Research Personnel
- From:Archives of Craniofacial Surgery 2018;19(3):168-174
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Safety, efficacy, and time to onset of effect of botulinum toxin type A is of importance to persons who seek improvement in glabellar frown lines, but this has not been well studied. The aim of this study was to determine the safety, efficacy, and onset of action of a newly developed botulinum toxin type A (Nabota) for the treatment of glabellar frown lines. METHODS: This was a single-arm, open-label, and phase 4 clinical study. Forty-two subjects with glabellar lines were treated with five times of intramuscular injection of 0.1 mL (4 U/0.1 mL) for a total of 20 U of Nabota. Efficacy and safety were assessed at 2, 3, 4, 5, and 14 days. Efficacy was assessed by the investigator and it was defined as a 1-point change on a 4-point scale. RESULTS: Improvement in glabellar frown lines at maximum frown was observed in 85.4% of subjects 2 days after administration. Improvement in glabellar lines at rest was observed in 51.2% of subjects 2 days after administration, and the proportion of subjects showing improvement increased with time. No severe adverse events were recorded. CONCLUSION: Onset of action was observed in the majority of subjects by 2 days after administration of Nabota. In addition, Nabota was found to be safe and effective for the treatment of glabellar frown lines.
